J17 Capital is a Canadian venture capital firm that specializes in growth equity investments, targeting middle to late-stage companies across North America. Their strategy focuses on partnering with growth-oriented businesses in diverse industries, with a particular emphasis on technology sectors such as consumer technologies, Web3, AI, and blockchain, to foster innovation and drive value creation.
33% of their portfolio is in Biotech & Life Sciences. Deal activity increased 100% year-over-year (2 deals in the last 12 months). Their most common stage is series-b (67% of deals). Average disclosed round size is $68.3M (across 3 rounds with reported amounts).
Portfolio
3
Fund Size
—
Top Stage
Series B
Last 12 Mo
2
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
3 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| CCambium Biomaterials | Series B | $100M | Jan 2026 |
 Cambium | Series B | $100M | Jan 2026 |
| GGAIB | Pre-Seed | $5M | Dec 2024 |
Top Co-Investors
8VC2 shared
MVP Ventures2 shared
Lockheed Martin Ventures2 shared
GSBackers2 shared
Veteran Ventures Capital2 shared
Vanderbilt University2 shared
Alumni Ventures Group2 shared
Gaingels2 shared
Hack VC1 shared
Hashed1 shared
Spartan Group1 shared
CMCC Global1 shared
Animoca Brands1 shared
M Ventures1 shared
Presto1 shared
IDG Capital1 shared
Inevitable Ventures1 shared
Jackson Moses1 shared
Last updated: 16 April 2026